Immunogenicity and safety of single‐dose, 13‐valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30764
Abstract: Children receiving immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The 13‐valent pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease in healthy children; however, there is an absence of literature regarding… read more here.
Keywords: conjugate vaccine; valent pneumococcal; oncology; pneumococcal conjugate ... See more keywords
Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®
Sign Up to like & getrecommendations! Published in 2022 at "Glycoconjugate Journal"
DOI: 10.1007/s10719-022-10050-2
Abstract: Bacterial capsular polysaccharide vaccines are generally poorly immunogenic in infants and older adults. The immunogenicity of capsular polysaccharide vaccines can be improved by conjugating them to immunogenic carrier proteins. One of the most recently licensed… read more here.
Keywords: tetanus toxoid; development; conjugate; conjugate vaccine ... See more keywords
Impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on acute mastoiditis in children in southern Israel: A 12-year retrospective comparative study (2005-2016).
Sign Up to like & getrecommendations! Published in 2020 at "International journal of pediatric otorhinolaryngology"
DOI: 10.1016/j.ijporl.2020.110485
Abstract: OBJECTIVES To define the trends in acute mastoiditis (AM) incidence, microbiology, complications and management in children, before and after the 13-valent pneumococcal conjugate vaccine (PVC13) introduction. METHODS Medical records of all AM patients read more here.
Keywords: acute mastoiditis; study; conjugate vaccine; valent pneumococcal ... See more keywords
Isolating polysaccharide IgG pneumococcal antibody responses by pre-adsorption of conjugate vaccine serotypes: A modified approach for the conjugate vaccine era.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of immunological methods"
DOI: 10.1016/j.jim.2020.112846
Abstract: BACKGROUND Assessment of pure polysaccharide response to the 23-valent pneumococcal polysaccharide vaccine (PPV23) can be biased by previous exposure to the conjugate vaccine (PCV). We applied pre-analytical modification to the existing ELISA by pre-incubating serum… read more here.
Keywords: adsorption; conjugate vaccine; pcv; vaccine ... See more keywords
Pneumococcal carriage among children after four years of routine 10-valent pneumococcal conjugate vaccine use in Brazil: The emergence of multidrug resistant serotype 6C.
Sign Up to like & getrecommendations! Published in 2017 at "Vaccine"
DOI: 10.1016/j.vaccine.2017.04.019
Abstract: BACKGROUND In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced free of charge in Brazil as part of the public immunization program. Here we investigated the carriage prevalence, colonization risk factors, capsular types, and… read more here.
Keywords: use; conjugate vaccine; valent pneumococcal; carriage ... See more keywords
Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children
Sign Up to like & getrecommendations! Published in 2018 at "Vaccine"
DOI: 10.1016/j.vaccine.2018.05.038
Abstract: Highlights • Vi-DT is safe and well tolerated in participants aged 2–45 years.• Significantly higher immune responses post Vi-DT compared to Vi polysaccharide vaccine.• No further increase in GMT post second dose as compared to post… read more here.
Keywords: typhoid conjugate; conjugate vaccine; safety immunogenicity; immunogenicity typhoid ... See more keywords
Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D).
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.01.008
Abstract: One dose of quadrivalent meningococcal conjugate vaccine (MenACWY) was first recommended for US adolescents (ages 11-12 years) in 2005 to protect against invasive meningococcal disease (IMD). In 2010, after evidence emerged about waning protection within 5 years… read more here.
Keywords: vaccine menacwy; quadrivalent meningococcal; conjugate vaccine; vaccine ... See more keywords
Development and pre-clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Neisseria meningitidis serogroup C.
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.07.053
Abstract: Significant improvement has been made in the development of vaccines against Neisseria meningitidis infections since the introduction of polysaccharide-protein conjugate vaccines. Conventional bacterial capsular polysaccharide (PS) based conjugate vaccines require unique and expensive manufacturing facilities,… read more here.
Keywords: conjugate; synthetic oligosaccharide; conjugate vaccine; protein conjugate ... See more keywords
Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.08.048
Abstract: INTRODUCTION Streptococcus pneumoniae is a leading cause of bacteremia, bacterial pneumonia, and meningitis, and is associated with substantial morbidity and mortality, particularly in those under 2 years of age and those over 65 years of age. While… read more here.
Keywords: healthy adults; conjugate vaccine; valent pneumococcal; vaccine ... See more keywords
Comparison of anti-capsular antibody quantity and functionality in children after different primary dose and booster schedules of 13 valent-pneumococcal conjugate vaccine.
Sign Up to like & getrecommendations! Published in 2020 at "Vaccine"
DOI: 10.1016/j.vaccine.2020.04.063
Abstract: Different schedules for pediatric use of the 13-valent pneumococcal conjugate vaccine (PCV-13) are recommended in different countries and the U.S. Advisory Committee on Immunization Practices (ACIP) has considered potential of changing from 3 primary doses… read more here.
Keywords: booster; antibody; conjugate vaccine; valent pneumococcal ... See more keywords
Clinically proven specification setting for a meningococcal serogroup a conjugate vaccine.
Sign Up to like & getrecommendations! Published in 2022 at "Vaccine"
DOI: 10.1016/j.vaccine.2022.04.053
Abstract: GSK is currently working to improve the commercial presentation of the licensed quadrivalent conjugate vaccine (Menveo) for use against meningococcal serogroup A, C, W, Y (MenACWY) infections. Menveo consists of a primary, lyophilized vial, containing… read more here.
Keywords: meningococcal serogroup; vaccine; conjugate vaccine; serogroup ... See more keywords